HUTCHMED (China) Ltd (STU:H7T1)
€ 16.1 0.5 (3.21%) Market Cap: 2.75 Bil Enterprise Value: 2.08 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 64/100

Hutchison China MediTech Ltd at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 09:00PM GMT
Release Date Price: €24.8 (+0.81%)
Xiao Yu Li
JP Morgan Chase & Co, Research Division - Analyst

Okay. Good afternoon, everyone. I'm David Li from JPMorgan Equity Research. Now it's my pleasure to introduce Mr. Hogg, the CEO of Hutchison China MediTech. Thank you.

Christian Hogg
Hutchison China MediTech Limited - CEO & Executive Director

Thank you, David. Okay. So we've got 25 minutes. I'm going to take everybody through a brief summary of our business and the current status and the outlook for the year. So on a high level, what is Hutchison China MediTech trying to achieve? We're obviously a China-based biotech that is endeavoring to become a global biotech. We have developed -- discovered and developed a range of small molecule targeted therapies, all of which have been designed for the global market. But obviously, with our location in China, and that being our home market, our first step is to maximize the potential in China. But we are very much focused on becoming a global based -- a global science-focused biotech based in China.

So looking at our operations, it sort of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot